PROMES: A clinical study in which researchers want to learn more about the safety profile of MESIGYNA (norethisterone enantate 50 mg and estradiol valerate 5 mg) used as a medication to prevent pregnancy for adult women in reproductive age in the Peruvian population at the outpatient clinic. (PROMES)
Clinical study in which researchers want to learn more about the safety profile of MESIGYNA used as a medication in routine clinical practice to prevent pregnancy. In order to find this out researchers will collect historic and treatment related data during initial visit and follow-up visits of adult women in reproductive age in the Peruvian population at the outpatient clinic. Mesigyna is a combined injectable birth control medication (norethindrone ethanate (50 mg) and estradiol valerate (5 mg)) for women given monthly.
- Adult female patients,18 to 45 years old with a Mesigyna prescription - Women for whom the decision to initiate contraception with Mesigyna was made as per investigator’s routine practice - Signed Informed Consent
- Women participating in an investigational program with interventions outside of routine clinical practice - Hypersensitivity to norethisterone enantate or estradiol valerate
Many locations, Peru
E-mail: [email protected]
Phone: (+)1-888-84 22937
PROMES: PROspective, Non-Interventional, observational, longitudinal study to describe the safety profile of MESIGYNA® (norethisterone enantate 50 mg and estradiol valerate 5 mg) as a contraceptive method for women in reproductive age at the outpatient clinic